Business & Industry

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Yuvraj — Tue, 02 Jun 2026 09:11:11 +0000

Eli Lilly and Company and Hanmi Pharm have officially finalized a comprehensive licensing agreement. Under the terms of the worldwide arrangement, Sonefpeglutide licensing is for global development, manufacturing, and commercialization, excluding the South Korean market. The financial framework includes a $75 million upfront payment to Hanmi, with the potential for up to $1.185 billion in […]

The post Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi first appeared on World Pharma Today.

Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement

Yuvraj — Mon, 01 Jun 2026 05:50:48 +0000

The Pfizer Innovent Cancer Deal has been finalized, establishing a global licensing and collaboration agreement valued at up to $10.5 billion. The transaction focuses on the research, development, and commercialization of 12 early-stage oncology programs. This arrangement combines the capabilities of both organizations to advance a specialized therapeutic pipeline targeting complex oncology indications. Under the […]

The post Pfizer and Innovent Finalize $10.5 Billion Global Oncology Agreement first appeared on World Pharma Today.

Nestlé and IdB Partner to Bring rCDI Preventive Therapy to Europe

Yuvraj — Mon, 01 Jun 2026 05:48:10 +0000

Nestlé Health Science and IdB Holding have officially announced a VOWST licensing agreement to develop and commercialize the oral therapy in Europe, subject to approval by the European Medicines Agency (EMA). This collaboration aims to expand European patient access to therapies preventing recurrent Clostridioides difficile infection, a severe gastrointestinal condition with limited management options. Currently […]

The post Nestlé and IdB Partner to Bring rCDI Preventive Therapy to Europe first appeared on World Pharma Today.

CordenPharma Seals AmbioPharm Deal to Expand Global Network

Yuvraj — Sat, 30 May 2026 08:25:37 +0000

CordenPharma, a global contract development and manufacturing organization specializing in complex drug modalities, has officially entered into an agreement to acquire AmbioPharm. The AmbioPharm Deal strengthens the company’s manufacturing presence in the United States while adding newly integrated production capabilities in Shanghai, China. The move allows CordenPharma to comprehensively support the growing global demand for […]

The post CordenPharma Seals AmbioPharm Deal to Expand Global Network first appeared on World Pharma Today.

MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours

Yuvraj — Fri, 29 May 2026 13:23:20 +0000

MSD and Adcendo have established a collaboration and supply agreement to evaluate the combination of ADCE-T02 and pembrolizumab. The companies are preparing for a Phase Ib solid tumour clinical trial targeting patients with advanced solid tumours. Adcendo will act as the sponsor for the solid tumour clinical trial, with MSD providing pembrolizumab. ADCE-T02 is an […]

The post MSD and Adcendo Initiate Phase Ib Collaboration for Solid Tumours first appeared on World Pharma Today.

Chemspec Europe 2026 Draws Global Industry Participation

Yuvraj — Fri, 29 May 2026 11:05:12 +0000

Chemspec Europe returned to Cologne on 6–7 May 2026, bringing together professionals from across the speciality chemicals sector despite ongoing economic and regulatory challenges facing the industry. The event welcomed 4,238 attendees representing 60 nations and featured 454 exhibitors from 28 countries, marking growth compared with the previous edition. Participants represented a broad range of […]

The post Chemspec Europe 2026 Draws Global Industry Participation first appeared on World Pharma Today.

Eli Lilly Returns to Infectious Disease with $3.8 Billion Acquisition Strategy

Yuvraj — Wed, 27 May 2026 05:29:27 +0000

After a seven-year absence from the sector, Eli Lilly is returning to the field through a trio of corporate purchases valued at more than $3.8 billion. This infectious disease M&A activity secures Curevo, LimmaTech Biologics, and Vaccine Company, firmly positioning the pharmaceutical organization within the vaccine development arena. The transactions represent a deliberate return to […]

The post Eli Lilly Returns to Infectious Disease with $3.8 Billion Acquisition Strategy first appeared on World Pharma Today.

FDA Grants Approval for Chronic Hepatitis Delta Virus Treatment from Gilead Sciences

Yuvraj — Sat, 23 May 2026 08:40:28 +0000

The U.S. Food and Drug Administration (FDA) has granted approval for Gilead Sciences’s Hepcludex, an experimental drug designed to treat chronic hepatitis delta virus (HDV). This rare and severe liver disease, which exclusively affects individuals already living with hepatitis B, can lead to organ failure, cancer, scarring, and death. Until this recent regulatory action, there […]

The post FDA Grants Approval for Chronic Hepatitis Delta Virus Treatment from Gilead Sciences first appeared on World Pharma Today.

Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems

Yuvraj — Sat, 23 May 2026 06:17:43 +0000

Bristol Myers Squibb has entered into a strategic agreement with Anthropic to deploy its Claude platform across global operations. This initiative moves beyond standard conversational tools, aiming to embed agentic AI capabilities directly into core workflows, including research, clinical development, and corporate functions. For industry executives, this move represents a significant effort to leverage advanced […]

The post Bristol Myers Squibb Integrates AI to Advance Manufacturing Quality Systems first appeared on World Pharma Today.

MHRA Launches Public Consultation on New Rare Disease Therapies Framework to Strengthen UK’s Global Position

Yuvraj — Thu, 21 May 2026 13:22:47 +0000

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on a proposed Rare Disease Therapies Framework a regulatory proposal that would introduce a new development and authorisation pathway for therapies targeting rare diseases in the United Kingdom. The consultation, published on 21 May 2026, is open until 30 July 2026, and […]

The post MHRA Launches Public Consultation on New Rare Disease Therapies Framework to Strengthen UK’s Global Position first appeared on World Pharma Today.